Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on February 18, 2021. The report addresses corporate governance changes, specifically regarding the Board of Directors, rather than financial performance results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance disclosures and does not contain financial statements or performance metrics.
Material Changes
- Director Departure: On February 18, 2021, Phebe N. Novakovic informed the Board of Directors of her decision not to stand for re-election at the 2021 annual shareholders meeting scheduled for April.
- Bylaw Amendment: On February 19, 2021, the Board amended Article III, Section 2 of the By-laws to reduce the Board size from fourteen to thirteen persons. This change is effective April 23, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the procedural changes to the Board composition.
Key Facts for Investor Verification
- Verify the exact date of the 2021 annual shareholders meeting to confirm the timing of Phebe N. Novakovic's departure.
- Confirm the effective date of the By-law amendment reducing the Board size to thirteen members (April 23, 2021).
- Review subsequent filings to identify the appointment of any new directors to fill the vacancy or adjust the Board composition.